RE:RE:RE:RE:Who is steering the ship right now? What does this mean for ProMIS Neurosciences?
ProMIS' announcement of the initiation of producer cell line development is significant as it is the first step on the path to IND drug approval. An Investigational New Drug designation by the FDA allows for faster development of a drug due to a high potential benefit for a certain disease. It usually involves an exemption from the FDA that allows a sponsor to ship an investigational drug across state lines to other clinical investigators.
The drug itself also has a "high degree of selectivity" when targeting toxic oligomers, and has been deemed safer and more effective when compared to less selective antibody products from Biogen, Eisai, and Lilly.
“ProMIS’ lead antibody program PMN310 offers potential “best in class” antibody therapy for Alzheimer’s disease,” statedProMIS Executive Chairman Eugene Williams. “With initiation of producer cell line development, we are re-focusing our efforts on advancing PMN310 into clinical development with the support of a distinguished Boston-based group of investors.”
quote=retiredcop]Gbathat.......I think you missed the point gp was trying to make... no companywill put out a Pr on a Friday before a long weekend unless it’s bad news....when you release good news you want it to build momentum and go up in value....so this is why I am saying there is a reason they made this on a Friday before a long weekend...[/quote]